The desire for patients to have a personalized approach to care is repeated throughout the ad, which was produced by Avalere ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

"The newer medications that are coming out, and a lot of them are approved, are much more focused on the problem," explains ...

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

Ahead Therapeutics SL has received positive feedback from the EMA on its way toward initiating regulatory toxicology studies for its lead program in myasthenia gravis. The feedback supports the ...

placebo-controlled Phase 2 study in patients with generalized Myasthenia Gravis who are acetylcholine receptor (AChR) antibody positive. Following an initial loading dose, DNTH103 will be ...

The US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and children aged 12 and older with generalized myasthenia gravis (gMG) who are ...

“We consistently hear from individuals living with myasthenia gravis who are hopeful for new treatment options ... safety profiles that offer sustained disease control. Anti-AChR and anti-MuSK ...

"FDA's approval of IMAAVY TM (nipocalimab-aahu) is an important step in expanding treatment options for people living with myasthenia gravis,” said Donald S. Wood, PhD, President and CEO, MDA. "With ...